Acadia Pharmaceuticals is a pioneering brand in neuroscience, dedicated to providing innovative solutions to those who need them most. With a focus on elevating life, Acadia has been at the forefront of healthcare for over 25 years. Led by a passionate and committed leadership team, Acadia is driven by a culture of curiosity, sustainability, belonging, and ethics.

Acadia offers FDA-approved treatments for Parkinson's Disease Psychosis and Rett Syndrome, including NUPLAZID® (pimavanserin) and DAYBUE™ (trofinetide). They also have a robust pipeline of therapies in various therapeutic areas where the unmet need remains high, such as Alzheimer's Disease Psychosis, Negative Symptoms of Schizophrenia (NSS), and Rett Syndrome. The brand also provides valuable resources to support industry leaders, strategic partners, and rigorous clinicians in their innovative work.

Acadia's dedication to corporate responsibility is rooted in ethics and sustainability, ensuring that their mission to fight disease is aligned with a sound internal environment. Join Acadia in their mission to make a difference for people living with neurological conditions and discover the brighter moments that shine through